ArticleBMC cardiovascular disorders2026
Decoding the shared genetic architecture of atherosclerotic cardiovascular disease: a genomic structural equation modeling analysis.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) represents a broad spectrum of phenotypes with shared pathology. However, the joint genetic architecture across different vascular beds remains incompletely characterized.
methodsWe applied genomic structural equation modeling (Genomic SEM) to integrate GWAS summary statistics from six ASCVD-related traits: coronary artery disease, myocardial infarction, ischemic stroke, peripheral artery disease, carotid intima-media thickness, and intracranial aneurysm. Downstream analyses included multivariate GWAS, fine-mapping, TWAS with FOCUS, MAGMA, pathway enrichment, cell-type and functional annotation, gsMAP and polygenic risk score.
resultsA single latent common factor model demonstrated an excellent fit to the genetic covariance matrix (CFI = 0.9837, SRMR = 0.1448). The multivariate GWAS identified 839 genome-wide significant SNPs, delineating 85 independent lead loci, of which 67 were novel. Integration of TWAS and FOCUS prioritized 6 high-confidence putative effector genes, including CDKN2B, MIA3, and NBEAL1. Functional enrichment highlighted lipid remodeling and apolipoprotein binding as predominant pathways. Notably, heritability was significantly localized in endothelial cell lineages across multiple tissues. Spatial mapping further identified the lung and kidney as key developmental tissue contexts for ASCVD genetic risk.
conclusionOur study provides a unified genetic framework for ASCVD, demonstrating that its shared liability is anchored in lipid homeostasis and systemic endothelial dysfunction. These findings offer a foundational atlas for early genomic-based risk stratification and therapeutic targeting.
Indexed as
Identifiers
42449234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.